All In Biotech

Drug Trial Radar · NCT06500793

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

A Single Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Capsule is Co Administered With Nafamostat as a Combination IR Solution and ER Capsule Formulation in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Nov 24, 2024

Primary completion

Dec 22, 2026

Study completion Apr 28, 2027

Sponsor

Lead sponsor
Ensysce BiosciencesIndustry
Sponsor type
Industry
Collaborators
Quotient Sciences; National Institute on Drug Abuse (NIDA)
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single dose dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release(ER) capsule prototypes.

Conditions

  • Pharmacokinetics
  • Healthy Volunteer

Interventions

  • PF614 capsuleDrug

    PF614 capsules (25-100 mg)

  • Nafamostat MesylateDrug

    Nafamostat IR/ER solution/beads/powder (total 1-25 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
  2. Pharmacokinetic Cmax [Maximum Plasma Concentration]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
  3. Pharmacokinetic C24 [Plasma concentration at 24 hours]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
  4. Pharmacokinetic AUC(0-last) [Area Under the Curve]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
  5. Pharmacokinetic AUC(0-inf) [Area Under the Curve]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
  6. Pharmacokinetic T1/2 [Half-life]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.